Adherium Ltd. · ASX:ADR
Adherium — Investor Presentation (July 2026)
24 slides from Adherium's investor presentation, July 2026
Slide 1: Adherium Investor Update
ASX: ADR Smarter Monitoring. Better Breathing. Lower Costs. Adherium Investor Update July 2026
Slide 2: Disclaimer and Forward-Looking Statement
Disclaimer and Forward-Looking Statement The material contained herein is of a general nature & has only been prepared as b. risks relating to possible partnering or other like arrangements a presentation aid. This presentation does NOT contain all of the information that may be required for evaluat
Slide 3: Investment Highlights
INTRODUCTION Investment Highlights Solving a significant and expensive healthcare problem 01 Asthma and COPD remain among healthcare's largest avoidable cost burdens, creating demand for scalable respiratory care. A business transformed over 12 months 02 12-month transformation from an R&D-focused,
Slide 4: Adherium has reached a commercial inflection point
INTRODUCTION Adherium has reached a commercial inflection point In the past 12-months, Adherium has established its recurring revenue platform, built enterprise care infrastructure, and is executing on its plan. The company is now scaling a patient base and platform that is reimbursed and showing co
Slide 5: Adherium's Management Team has evolved significantly
Adherium’s Management Team has evolved significantly, and our focus on growing our patient base is clear Dawn Bitz John Perry Tom Quinlan Keven Gessner David Haddad Hetal Dhruve CFO Head of Product Head of Medical and Clinical Affairs Chief Executive Officer Chief Commercial Officer Non-Executive Di
Slide 6: Adherium's Connected Respiratory Care
INTRODUCTION Adherium’s Connected Respiratory Care Connected care uses proprietary technology and real-time patient data to extend care beyond the clinic, helping improve outcomes while reducing avoidable healthcare costs. Devices, data, AI and care workflows - one respiratory operating system SMART
Slide 7: Intermountain Health (IMH)
Intermountain Health (IMH) Leading US health system with 33 hospitals, 385 clinics, and 250k COPD/Asthma patients Owns Select Health, a nonprofit health plan with more than 1.1 million members iCARE Quality Improvement Program Landmark independent program demonstrating robust clinical outcomes using
Slide 8: Intermountain Health: iCARE
iCARE Quality INTRODUCTION Improvement Study Intermountain Health: iCARE One of the largest respiratory monitoring programs conducted to date - results presented at American Thoracic Society May 2026 (ATS 2026). 57% 50% 20% 92% reduction in total cost of care fewer hospital admissions fewer emergenc
Slide 9: Value-based contracts benefit from intelligent measurement
INTRODUCTION Value-based contracts benefit from intelligent measurement Outcomes contracts are only as good as the data underneath them. Adherium owns the layer that measures. IN F ER RED M E AS U R E D How the market measures adherence today How Hailie® instruments the same patient • Refill and cla
Slide 10: ~40M Americans live with chronic respiratory disease
01 THE HEALTHCARE PROBLEM ~40M Americans live with chronic respiratory disease3 Medication non-adherence and poor technique are primary causes of avoidable hospitalisations, emergency department visits, and billions of dollars of costs to the healthcare system12,13 Includes diseases like Asthma and
Slide 11: A US $120B Annual Burden. A $20B Total Addressable Market.
01 THE HEALTHCARE PROBLEM A US $120B Annual Burden. A $20B Total Addressable Market. Total Addressable Market (TAM) = ~US$20b across ~22M patients* U.S. COPD U.S. Asthma Patients Patients All patients All patients 11M 27M Moderate/Severe/ Severe/Uncontrolled Very Severe 8M 14M ~$18K/yr per severe CO
Slide 12: Why now? Two US healthcare shifts, accelerating adoption.
01 THE HEALTHCARE PROBLEM Why now? Two US healthcare shifts, accelerating adoption. Remote Patient Monitoring (RPM) Value-Based Care (VBC) rewards outcomes reimbursement is expanding HEALTHCARE IS PAYING PROVIDERS TO MONITOR PROVIDERS NOW BENEFIT FINANCIALLY WHEN MORE PATIENTS THAN EVER BEFORE. HOSP
Slide 13: RPM Builds The Platform. Value-Based Care Monetises It.
02 A TRANSFORMED BUSINESS RPM Builds The Platform. Value-Based Care Monetises It. Over 2,600 active RPM patients on the Hailie Platform provide commercial and clinical validation for value-based care RPM EARNS THE CONTRACT SAME PLATFORM VBC CONTRACTS Cost to Serve The Cohort The Model Shifts Margin
Slide 14: A Key Learning. The Right Patient Changes Everything.
04 COMPENDIUM OF EVIDENCE A Key Learning. The Right Patient Changes Everything. Recent cohorts taught us exactly who to enroll – a learning that strengthens RPM economics and sharpens value-based care targeting WHAT WE SAW WHAT THE DATA SHOWS THE ACTION WHY IT MATTERS Recent Churn Severity = retenti
Slide 15: Evidence Compounds. The Moat Deepens.
04 COMPENDIUM OF EVIDENCE Evidence Compounds. The Moat Deepens. Three layers of evidence reinforce each other – together they create an advantage competitors cannot shortcut ESTABLISHED SCIENCE PROVEN WITH PARTNERS PROPRIETARY SIGNAL THE ADHERIUM ADVANTAGE The Clinical Case Proof At Scale Dose-By-Do
Slide 16: We get paid a share of what we save.
05 VALUE-BASED CARE We get paid a share of what we save. Money and risk flow down this chain. Fee-for-service pays for volume, so risk is shifting to those who can manage it, and outcomes are the new currency. Whoever carries the cost of a respiratory population is our buyer. Why these contracts exi
Slide 17: Every Major Chronic Disease Has Its Digital Owners. Respiratory Is Unclaimed.
05 VALUE-BASED CARE Every Major Chronic Disease Has Its Digital Owners. Respiratory Is Unclaimed. Outcomes-based chronic-care models are proven and richly rewarded – value has been created in every top cost category except the one we address CATEGORY OWNED CATEGORY OWNED CATEGORY OWNED CATEGORY OWNE
Slide 18: The Value Pool At A Single National Payer.
05 VALUE-BASED CARE The Value Pool At A Single National Payer. One example, iCARE percentages only: $18K annual direct cost per severe patient × 50% observed reduction in hospitalisation-driven costs ≈ $9K savings per enrolled patient per year THE BOOK THE PATIENTS THE PLATFORM THE VALUE 19M Members
Slide 19: Commercial momentum: the buying signals are stacking up
05 VALUE-BASED CARE Commercial momentum: the buying signals are stacking up National payers at the table Committee-level diligence Multiple national payers engaged in formal, NDA- Finance, pharmacy and medical teams actively governed evaluations of the composite respiratory modelling cost savings -
Slide 20: Our catalyst calendar
06 KEY TAKE-AWAYS Our catalyst calendar 1Q FY27 2Q FY27 2Q/3Q FY28 Scale & evidence The inflection VBC economics • Continue growing RPM patient • First value-based care pilot / contract • Recognise shared-savings revenue recurring revenue quarterly signed from first value-based care pilot / contract
Slide 21: What we have achieved; now positioned to deliver on catalyst pipeline
06 KEY TAKE-AWAYS What we have achieved; now positioned to deliver on catalyst pipeline The platform built. The model proven. Scaling has begun Every patient compounds our competitive advantage Multiple growth horizons THE NEXT SIX MONTHS – deepen existing partnerships · target the risk-holders · wi
Slide 22: Thank You
Thank You For more information, contact: John Perry, Chief Commercial Officer Perryj@adherium.com NEW LEADERSHIP FOR THE LEAP 20+ years building value-based care and payer partnerships - Optum, Signify Health, Guidehealth - nine eight-figure partnerships closed, including Emory, Advocate, Ascension,
Slide 23: Key Terms, and Acronyms
Key Terms, and Acronyms Commercial / US Healthcare Industry Terms ACO Accountable Care Organization LTV Lifetime Value ADR Adherium Limited (ASX: ADR) MA Medicare Advantage AI Artificial Intelligence MDI Metered Dose Inhaler AIRQ Asthma Impairment and Risk Questionnaire MMA Medication Management for
Slide 24: References
References 1. Melani A, et al. Inhaler mishandling remains common in real life and is associated with reduced disease control. Respir Med. 2011;105(6):930-938. 2. Nurmagambetov T, Kuwahara R, Garbe P. The Economic Burden of Asthma in the United States, 2008-2013. Ann Am Thorac Soc. 2018;15(3):348-35